PMID- 25757076
OWN - NLM
STAT- MEDLINE
DCOM- 20160113
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 3
DP  - 2015
TI  - The time window for therapy with peptide nanofibers combined with autologous bone 
      marrow cells in pigs after acute myocardial infarction.
PG  - e0115430
LID - 10.1371/journal.pone.0115430 [doi]
LID - e0115430
AB  - BACKGROUND: We previously showed that injection of peptide nanofibers (NF) 
      combined with autologous bone marrow mononuclear cells (MNC) immediately after 
      coronary artery ligation improves cardiac performance in pigs. To evaluate the 
      clinical feasibility, this study was performed to determine the therapeutic time 
      window for NF/MNC therapy in acute myocardial infarction (MI). METHODS AND 
      RESULTS: A total of 45 adult minipigs were randomly grouped into 7 groups: sham 
      or MI plus treatment with NS (normal saline), or NF or MNC alone at 1 day (1D) 
      post-MI, or NF/MNC at 1, 4, or 7 days post-MI (N>/=6). Cardiac function was 
      assessed by echocardiography and ventricular catheterization. Compared with the 
      NS control, pigs treated with NF/MNC at 1 day post-MI (NF/MC-1D) had the greatest 
      improvement in left ventricle ejection fraction (LVEF; 55.1+/-1.6%; P<0.01 vs. NS) 
      2 months after MI. In contrast, pigs treated with either NF/MNC-4D or NF/MNC-7D 
      showed 48.9+/-0.8% (P<0.05 vs. NS) and 43.5+/-2.3% (n.s. vs. NS) improvements, 
      respectively. The +dP/dt and -dP/dt, infarct size and interstitial collagen 
      content were also improved in the NF/MNC-1D and -4D groups but not in the -7D 
      group. Mechanistically, MNC quality and the states of systemic inflammation and 
      damaged heart tissue influence the therapeutic efficiency of NF/MNC therapy, as 
      revealed by another independent study using 16 pigs. CONCLUSIONS: Injection of 
      NF/MNC at 1 or 4 days, but not at 7 days post-MI, improves cardiac performance 
      and prevents ventricular remodeling, confirming the importance of early 
      intervention when using this therapy for acute MI.
FAU - Chang, Ming-Yao
AU  - Chang MY
AD  - Department of Biomedical Engineering, National Cheng Kung University, Tainan, 
      Taiwan.
FAU - Chang, Chih-Han
AU  - Chang CH
AD  - Department of Biomedical Engineering, National Cheng Kung University, Tainan, 
      Taiwan.
FAU - Chen, Chien-Hsi
AU  - Chen CH
AD  - Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
FAU - Cheng, Bill
AU  - Cheng B
AD  - Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
FAU - Lin, Yi-Dong
AU  - Lin YD
AD  - Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
FAU - Luo, Chwan-Yau
AU  - Luo CY
AD  - Department of Surgery, National Cheng Kung University & Hospital, Tainan, Taiwan.
FAU - Wu, Hua-Lin
AU  - Wu HL
AD  - Department of Biochemistry and Molecular Biology, National Cheng Kung University, 
      Tainan, Taiwan.
FAU - Yang, Yu-Jen
AU  - Yang YJ
AD  - Department of Surgery, National Cheng Kung University & Hospital, Tainan, Taiwan.
FAU - Chen, Jyh-Hong
AU  - Chen JH
AD  - Department of Internal Medicine, National Cheng Kung University & Hospital, 
      Tainan, Taiwan.
FAU - Hsieh, Patrick C H
AU  - Hsieh PC
AD  - Department of Biomedical Engineering, National Cheng Kung University, Tainan, 
      Taiwan; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan; 
      Department of Surgery, National Cheng Kung University & Hospital, Tainan, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150310
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Peptides)
SB  - IM
MH  - Animals
MH  - Bone Marrow Transplantation
MH  - Cell Differentiation
MH  - Drug Administration Schedule
MH  - Endothelial Cells/physiology
MH  - Endothelium, Vascular/pathology
MH  - Myocardial Infarction/pathology/*therapy
MH  - Myocardium/pathology
MH  - Nanofibers/*therapeutic use
MH  - Peptides/therapeutic use
MH  - Swine
MH  - Swine, Miniature
MH  - Time Factors
MH  - Transplantation, Autologous
MH  - Ventricular Remodeling
PMC - PMC4355625
COIS- Competing Interests: Patrick C.H. Hsieh has read the journal's policy and the 
      authors of this manuscript have the following competing interests: Dr. Patrick 
      Hsieh received research support from Celgene Cellular Therapeutics and Meridigen 
      Biotech Co. Although the authors had received research support from Celgene 
      Cellular Therapeutics and Meridigen Biotech Co., this does not alter the authors' 
      adherence to PLOS ONE policies on sharing data and materials.
EDAT- 2015/03/11 06:00
MHDA- 2016/01/14 06:00
PMCR- 2015/03/10
CRDT- 2015/03/11 06:00
PHST- 2014/09/14 00:00 [received]
PHST- 2014/11/23 00:00 [accepted]
PHST- 2015/03/11 06:00 [entrez]
PHST- 2015/03/11 06:00 [pubmed]
PHST- 2016/01/14 06:00 [medline]
PHST- 2015/03/10 00:00 [pmc-release]
AID - PONE-D-14-41355 [pii]
AID - 10.1371/journal.pone.0115430 [doi]
PST - epublish
SO  - PLoS One. 2015 Mar 10;10(3):e0115430. doi: 10.1371/journal.pone.0115430. 
      eCollection 2015.